This is a third-party event.
Jon Burrows, CEO at Oxford Biodynamics will present the FY results (published on 28th January) and provides an update on corporate performance.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Register in advance for this webinar:
After registering, you will receive a confirmation email containing information about how to join the webinar.
Please note that this webinar has been organised by Yellowstone Advisory